MedTech Innovator

Nanobiofab, founded in 2015 and based in Frederick, Maryland, specializes in the development of wearable, smart healthcare and medical devices utilizing nanotechnology for both humans and pets. The company is known for its product, iNose, which enables users to detect, track, and monitor their body's skin vapor-print. This device wirelessly connects to mobile phones to help individuals assess their fat burning rate and evaluate the effectiveness of their exercise routines. Additionally, it provides insights into the effects of dietary choices over time and tracks metabolic rates. Beyond consumer products, Nanobiofab also offers technology and services aimed at accelerating nanomaterial research and development, including nanoprinting solutions and artificial intelligence sensors for telemedicine and personalized healthcare applications.

INOPASE is a medical device company focused on the development of wirelessly powered, closed-loop implantable neuromodulation technologies. The company is currently advancing two key products: a closed-loop sacral neuromodulation system aimed at treating overactive bladder and a closed-loop brain neuromodulation device designed for epilepsy management. INOPASE's platform utilizes advanced algorithms to deliver personalized treatment plans by detecting symptoms and providing targeted stimulation therapy, positioning the company as a significant player in the treatment of chronic neurological diseases.

Ortho-tag specializes in developing innovative technologies that facilitate wireless communication between digital health applications and implanted medical devices. Their in-vivo platform enables real-time data exchange and in-body communication through a proprietary method known as transcutaneous volume conduction. This technology enhances the functionality of smart medical implants by allowing for efficient powering, data storage, and nano diagnostic capabilities. By bridging the gap between digital health technologies and the human body, Ortho-tag aims to improve the integration and performance of medical devices, thereby enhancing patient care and monitoring.

NXgenPort Inc focuses on enhancing cancer care through its innovative digital health technology, which includes an implanted Smart Port for remote patient monitoring between chemotherapy sessions. This system measures vital health metrics, such as cell counts and heart function, allowing for timely alerts to physicians regarding potential infections. By reducing hospitalizations and collecting critical physiological data, NXgenPort aims to improve overall patient outcomes. Additionally, the technology offers significant advantages for cancer researchers and drug delivery stakeholders by enabling them to remotely assess a participant's biological response to various interventions, thereby supporting more effective treatment strategies.

Healthcare is moving to the outpatient setting to save costs, but at home patients struggle with medication adherence and they are readmitted at alarming rates. Hospitals send 1.4 million patients home for 4-6 weeks to administer their own IV antibiotics every year. Twenty percent of patients on outpatient parenteral antimicrobial therapy (OPAT) are readmitted, each costing $80,000 on average. This is a $22.4 billion problem. Clinicians at the 12,200 home infusion providers in the US have no objective way to identify non-adherence to intervene and prevent readmissions. Rather, they call patients to detect non-adherence, which is time-consuming, inaccurate, and prone to reporting bias. They need a better tool than a phone to monitor adherence. The solution is HIVE’s patent pending CloudConnect smart catheter. CloudConnect is a reinvented IV line with a simple embedded mechanoelectrical sensor that detects when a medication source is connected. CloudConnect wirelessly sends this information to electronic medical records. HIVE’s value proposition is that clinicians can detect non-adherence in real time and make treatment decisions and prevent costly readmissions based on objective data. HIVE offers CloudConnect as an alternative to the need for clinicians to call every patient with standard IV lines.

Lazurite is a pre-revenue medical device startup that focuses on developing innovative technologies to enhance surgical procedures. The company has secured approximately $18 million in funding from institutional investors, high-net-worth individuals, and over 50 physician advocates. Lazurite aims to revolutionize the operating room with its product lineup, which includes the ArthroFree™ and ORFree™ wireless camera systems. These platforms represent the first fully wireless minimally invasive surgical camera technologies, designed to improve efficiency and safety in surgical environments. The company’s advancements are based on its proprietary Meridiem™ light engine technology, which underpins its commitment to providing solutions that replace traditional, cumbersome wired systems with more effective and streamlined wireless alternatives.

Cari Health develops remote medication monitors that allow clinicians to prescribe medications and receive real-time reporting on medication levels. Its monitors are wireless sensors that are worn on the patient's skin and continuously send data about medication levels to the cloud. The company was founded in 2015, incorporated in 2021 and is headquartered in San Diego, California.

Nanowear, Inc. specializes in the development of textile-based nanosensor technology that facilitates wireless and real-time electrophysiological monitoring. Founded in 2014 and headquartered in Brooklyn, New York, the company offers products such as SimplECG, a remote cardiac monitoring undergarment, and SimpleSense, which focuses on the monitoring and management of congestive heart failure. These garments collect multi-channel electrocardiogram (ECG), heart rate, and respiratory rate data, which is transmitted to a web-based portal accessible by healthcare professionals via a mobile application. Nanowear's technology serves various sectors, including cardiac and neurological health, industrial safety, government, sports medicine, and performance diagnostics, providing accurate and continuous diagnostic data in a cost-effective and unobtrusive manner. The company also maintains a research and development facility in University Park, Pennsylvania.

Synotrac is a company focused on developing innovative sensor technology for real-time infection detection in vivo. Its patent-pending implantable device is designed to monitor infection at the source, specifically after joint surgery. By analyzing the body's immune response, the device provides a dynamic assessment of the healing process, allowing for the early detection of infections. The information gathered is relayed to a smartphone, facilitating prompt analysis and reporting. This technology aims to reduce the need for hospital visits and additional surgeries, enabling patients to receive timely measurements and care.

TinyKicks is a technology company based in Irvine, California, founded in 2014 by France Helfer. The company specializes in developing a wireless smart sensor system that captures fetal movement to promote healthy pregnancy outcomes. Its flagship product, the TinyKicks eMotion fetal activity monitor, is a wearable device that detects and distinguishes between the baby's kicks and the mother's movements. This continuous monitoring system automatically uploads data to the user's smartphone, allowing pregnant women to track their baby's activity. By leveraging machine learning algorithms, TinyKicks can identify abnormal fetal movement patterns, alerting users to potential complications and thereby reducing the costs associated with pregnancy-related issues.